An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide
Open Access
- 31 August 2023
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 13 (17) , 2820
Abstract
Neuroendocrine neoplasms (NENs) are a heterogeneous group of diseases that are characterized by different behavior and clinical manifestations. The diagnosis and management of this group of tumors are challenging due to tumor complexity and lack of precise and widely validated biomarkers. Indeed, the current circulating mono-analyte biomarkers (such as chromogranin A) are ineffective in describing such complex tumors due to their poor sensitivity and specificity. In contrast, multi-analytical circulating biomarkers (including NETest) are emerging as more effective tools to determine the real-time profile of the disease, both in terms of accurate diagnosis and effective treatment. In this review, we will analyze the capabilities and limitations of different circulating biomarkers focusing on three relevant questions: (1) accurate and early diagnosis; (2) monitoring of disease progression and response to therapy; and (3) detection of early relapse.Keywords
Funding Information
- AIRC fellowship for Italy (28054, ERP-2017-23671129, 26343)
- Italian Ministry of Health (28054, ERP-2017-23671129, 26343)
- Associazione Italiana per la Ricerca sul Cancro (28054, ERP-2017-23671129, 26343)
This publication has 168 references indexed in Scilit:
- The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional StudyPLOS ONE, 2013
- MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease ControlsClinical Cancer Research, 2013
- The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in BloodPLOS ONE, 2013
- Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axisNeuropeptides, 2012
- Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragmentsEuropean Journal of Cancer, 2012
- Biomarkers and Molecular Imaging in Gastroenteropancreatic Neuroendocrine TumorsHormone and Metabolic Research, 2011
- 6564 POSTER Correlation of PFS With Early Response of Chromogranin A and 5-hydroxyindoleacetic Acid Levels in Pts With Advanced Neuroendocrine Tumours: Phase III RADIANT-2 Study ResultsEuropean Journal of Cancer, 2011
- Hypercalcitoninemia is not Pathognomonic of Medullary Thyroid CarcinomaClinics, 2009
- MicroRNAs: small RNAs with a big role in gene regulationNature Reviews Genetics, 2004
- Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: Value of measurement in diagnosis and treatmentDigestive Diseases and Sciences, 1978